AHPRA Cosmetic Advertising Enforcement Strategy Update 2026

What Changed in the AHPRA Cosmetic Advertising Hub?

AHPRA has restructured its cosmetic surgery advertising guidance hub by adding three major new resource categories—enforcement strategy documentation, compliance case studies, and Chinese medicine-specific examples—while simultaneously removing previously available fact sheets on injectables and non-surgical cosmetic procedures. This represents a shift from procedural guidance toward enforcement transparency and profession-specific compliance education.

The changes detected on 26 April 2026 show a fundamental reorganisation of how AHPRA presents cosmetic advertising compliance information. The new structure emphasises how AHPRA will enforce the existing guidelines rather than expanding the guidelines themselves.

The most significant addition is the Advertising compliance and enforcement strategy document. This is the first time AHPRA has publicly detailed its internal processes for handling advertising complaints, including triage criteria, risk assessment frameworks, and escalation pathways. Practitioners can now understand how AHPRA prioritises complaints and what factors increase enforcement likelihood.

The Advertising complaints guidance provides practitioners with clear information about how complaints are lodged, investigated, and resolved. This transparency allows practitioners to understand the complaint lifecycle and their rights during investigations.

Two new case study collections have been added: Case studies: Shared Code of conduct and Case studies: understanding the Code of conduct. These provide real-world scenarios showing how advertising conduct intersects with the broader professional conduct obligations under the various National Boards' codes of conduct.

The addition of Check your advertising: Chinese medicine examples is particularly notable. This is the first profession-specific advertising guidance published in the cosmetic surgery hub, acknowledging that Chinese medicine practitioners are increasingly offering cosmetic services such as facial acupuncture, cupping for body contouring, and herbal treatments marketed for skin conditions.

What Was Removed

Three resources have been withdrawn from the hub:

• Fact sheet on injectables — Previously provided guidance on advertising prescription injectable cosmetic treatments
• Our response to the cosmetic surgery review — AHPRA's commentary on regulatory reforms following the 2023 cosmetic surgery review
• Resources for performing non-surgical cosmetic procedures — Guidance on non-surgical cosmetic procedure standards and advertising

AHPRA has not published an explanation for these removals. The withdrawal of injectable-specific guidance is particularly significant given the September 2025 updates that introduced stringent restrictions on advertising prescription injectables for cosmetic purposes.

What Changed vs. What Stayed the Same?

The underlying advertising guidelines remain unchanged—this update modifies how AHPRA communicates compliance expectations and enforcement processes, not the substantive rules themselves. The September 2025 restrictions on higher-risk cosmetic procedures, including the ban on naming prescription injectables and price advertising prohibitions, remain in full effect.

The September 2025 updates referenced in the AHPRA cosmetic surgery advertising guidelines update remain the substantive regulatory framework. This April 2026 hub restructure is about enforcement transparency and profession-specific education, not new rules.

Why Does Enforcement Strategy Transparency Matter for Practitioners?

The publication of AHPRA's enforcement strategy allows practitioners to understand how advertising complaints are assessed, what factors trigger escalated enforcement action, and how to respond effectively during investigations. This transparency reduces uncertainty and enables proactive compliance management rather than reactive crisis response.

Previously, practitioners facing advertising complaints had limited visibility into AHPRA's internal assessment processes. The complaint would arrive, often months after publication, with little context about severity assessment or likely outcomes. The new enforcement strategy documentation changes this dynamic entirely.

Practitioners can now understand the risk-based triage framework AHPRA uses to prioritise complaints. High-risk factors that escalate enforcement action include:

• Advertising targeting vulnerable populations (individuals with body dysmorphia, eating disorders, or psychological distress)
• Repeated violations after previous warnings or undertakings
• Advertising that creates serious public health risks (encouraging unnecessary procedures, trivialising surgical risks)
• Deliberate or reckless disregard for advertising guidelines
• Advertising by practitioners with concurrent clinical performance concerns

Understanding these escalation factors allows practitioners to conduct internal risk assessments of their advertising content. Material that falls into high-risk categories warrants immediate review and remediation, even without a formal complaint.

The enforcement strategy also clarifies the spectrum of regulatory responses available to AHPRA, from education and voluntary undertakings through to formal cautions, conditions on registration, and prosecution. This helps practitioners understand that not all complaints result in formal disciplinary action—early cooperation and swift remediation can result in educational outcomes rather than sanctions.

What Do the Chinese Medicine Examples Reveal About AHPRA's Focus?

The addition of Chinese medicine-specific advertising examples signals AHPRA's recognition that cosmetic services are no longer dominated by medical practitioners and surgeons. Non-medical health practitioners—including Chinese medicine practitioners, nurses, and dentists—now constitute a significant portion of the cosmetic services market, and AHPRA is tailoring compliance education accordingly.

Chinese medicine practitioners have increasingly marketed cosmetic services including facial acupuncture for wrinkle reduction, gua sha and facial cupping for skin rejuvenation, herbal formulations for acne and pigmentation, and traditional techniques marketed as alternatives to injectables or surgery. These services fall squarely within AHPRA's advertising jurisdiction when offered by registered practitioners.

The Chinese medicine examples likely address common compliance gaps including:

• Outcome claims for cosmetic treatments that cannot be substantiated with clinical evidence meeting AHPRA's standards
• Before/after images without proper disclaimers, consent, or showing unrealistic results
• Marketing cosmetic services as "natural alternatives" to regulated treatments in ways that create unrealistic expectations
• Using patient testimonials or reviews to promote cosmetic services
• Inadequate practitioner identification in advertising (AHPRA registration number, qualifications)

The publication of profession-specific examples suggests AHPRA may develop similar resources for other non-medical professions offering cosmetic services. Dental practitioners advertising teeth whitening, orthodontics for cosmetic purposes, and facial aesthetic treatments, as well as nurses offering cosmetic injectables and skin treatments, may see targeted guidance in future updates.

This profession-specific approach reflects AHPRA's maturation in regulating the diversified cosmetic services market. Early guidance focused almost exclusively on medical practitioners and surgeons performing surgical procedures. The regulatory focus has now expanded to encompass the full spectrum of registered practitioners offering any cosmetic service, surgical or non-surgical, medical or traditional.

What Does the Removal of Injectable Resources Mean?

The withdrawal of the injectable fact sheet and non-surgical procedure resources creates a guidance gap at a time when these procedures face the most stringent advertising restrictions. Practitioners must now rely solely on the main advertising guidelines and September 2025 updates without procedure-specific interpretation documents.

The timing of this removal is significant. The September 2025 updates introduced sweeping restrictions on advertising prescription injectables for cosmetic purposes, including the ban on product naming, hashtag prohibitions, and price advertising restrictions. Many practitioners have struggled to interpret these requirements, particularly around what constitutes "advertising" versus educational content, and how to market cosmetic injectable services without naming the products used.

With the removal of the injectable fact sheet, practitioners lose access to worked examples and AHPRA's interpretive guidance on these nuanced issues. This may reflect one of two strategic positions by AHPRA:

Possibility 1: Consolidation. AHPRA may be consolidating all guidance into the main advertising guidelines document to avoid conflicting or outdated information across multiple resources. The September 2025 updates may have rendered the previous fact sheet obsolete.

Possibility 2: Enforcement focus. AHPRA may be deliberately reducing interpretive guidance to establish clear bright-line rules without exceptions or qualifications. The message: the restrictions are absolute, and practitioners should not look for loopholes or edge cases.

Regardless of AHPRA's reasoning, practitioners advertising prescription injectable cosmetic treatments must ensure strict compliance with the September 2025 restrictions. The absence of a fact sheet does not create ambiguity—the prohibitions remain clear and enforceable. Refer to our detailed analysis in AHPRA Updates Cosmetic Surgery Advertising Guidelines for comprehensive coverage of the injectable advertising restrictions.

What Practical Value Do the Case Studies Provide?

The new case study collections provide concrete examples of how advertising conduct intersects with broader Code of Conduct obligations, showing practitioners the cumulative compliance risk when advertising violations occur alongside clinical performance or professional conduct concerns.

The case studies appear to focus on the intersection between advertising conduct and Section 8 of the Medical Board of Australia's Code of Conduct (Public Communications), as well as equivalent provisions in other National Boards' codes. This intersection is critical because advertising violations are rarely assessed in isolation—they typically occur within a broader context of practitioner conduct.

Case studies likely illustrate scenarios such as:

• A practitioner using patient before/after images without proper consent, violating both advertising guidelines and patient confidentiality obligations
• Superiority claims in advertising that cannot be substantiated, demonstrating both misleading advertising and failure to maintain professional standards
• Social media content that trivialises surgical risks while also failing to provide adequate informed consent information to prospective patients
• Responding to negative reviews in ways that breach patient confidentiality while attempting to manage online reputation

These case studies help practitioners understand that advertising compliance is not merely a technical checklist exercise—it reflects fundamental professional obligations around honesty, patient respect, informed consent, and maintaining public trust in the health professions.

The "Shared Code of conduct" case studies are particularly valuable for practitioners in multi-disciplinary cosmetic clinics where medical practitioners, nurses, and other health professionals work together. These scenarios likely show how advertising responsibilities are allocated when multiple practitioners are involved in creating or approving marketing content.